Entering text into the input field will update the search result below

Zai Lab on deck for IPO

Aug. 21, 2017 12:27 PM ETZai Lab Limited (ZLAB) StockZLABBy: Douglas W. House, SA News Editor1 Comment
  • Zai Lab Limited (NASDAQ:ZLAB) is set for its $115M IPO of ordinary shares.
  • The Shanghai, China-based biopharmaceutical firm develops proprietary therapeutics to address large unmet medical needs in China.
  • Its lead candidate is PARP inhibitor ZL-2306, currently being evaluated in several cancers, including breast and ovarian. Candidate #2 is broad-spectrum antibiotic omadacycline (ZL-2401) for the treatment of ABSSSI, CABP and urinary tract infections. Candidate #3 is cancer candidate ZL-2301 (brivanib), a dual inhibitor of VEGF and FGF (fibroblast growth factor) receptors.
  • 2016 Financials ($M): Operating Expenses: (38.5) (+136.2%); Net Loss: (37.5) (-108.3%); Cash Burn: (32.2) (-180.0%).

Recommended For You

About ZLAB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ZLAB--
Zai Lab Limited